Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Other financing activities (2020 - 2025)

Ligand Pharmaceuticals' Other financing activities history spans 5 years, with the latest figure at $617000.0 for Q4 2025.

  • For Q4 2025, Other financing activities rose 422.88% year-over-year to $617000.0; the TTM value through Dec 2025 reached $15.5 million, up 3545.07%, while the annual FY2025 figure was $15.5 million, 3545.07% up from the prior year.
  • Other financing activities for Q4 2025 was $617000.0 at Ligand Pharmaceuticals, down from $14.8 million in the prior quarter.
  • Across five years, Other financing activities topped out at $14.8 million in Q3 2025 and bottomed at -$121000.0 in Q1 2022.
  • The 4-year median for Other financing activities is $71000.0 (2025), against an average of $1.3 million.
  • The largest YoY upside for Other financing activities was 6965.71% in 2025 against a maximum downside of 96.49% in 2025.
  • A 4-year view of Other financing activities shows it stood at $42000.0 in 2022, then surged by 2159.52% to $949000.0 in 2023, then crashed by 87.57% to $118000.0 in 2024, then surged by 422.88% to $617000.0 in 2025.
  • Per Business Quant, the three most recent readings for LGND's Other financing activities are $617000.0 (Q4 2025), $14.8 million (Q3 2025), and $2000.0 (Q2 2025).